HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has announced the acceptance of its New Drug Application (NDA) by China’s National Medical Products Administration for the drug tazemetostat, aimed at treating relapsed or refractory follicular lymphoma, and has been granted Priority Review status. Tazemetostat, developed by Epizyme, Inc., is already approved in the U.S. and Japan for similar uses and has shown promise in a Phase II study in China. This milestone indicates significant progress in HUTCHMED’s strategic collaboration to bring tazemetostat to the Chinese market and potentially offer a new treatment option for follicular lymphoma patients.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
